- Home
- COGT vs ATLC Comparison
COGT vs ATLC Comparison
Compare COGT & ATLC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- COGT
- ATLC
- Stock Information
- Founded
- COGT 2014
- ATLC 1996
- Country
- COGT United States
- ATLC United States
- Employees
- COGT N/A
- ATLC N/A
- Industry
- COGT Biotechnology: Pharmaceutical Preparations
- ATLC Finance: Consumer Services
- Sector
- COGT Health Care
- ATLC Finance
- Exchange
- COGT Nasdaq
- ATLC Nasdaq
- Market Cap
- COGT 1.1B
- ATLC 900.3M
- IPO Year
- COGT 2018
- ATLC 1999
- Fundamental
- Price
- COGT $11.70
- ATLC $61.55
- Analyst Decision
- COGT Strong Buy
- ATLC Buy
- Analyst Count
- COGT 9
- ATLC 7
- Target Price
- COGT $20.25
- ATLC $66.14
- AVG Volume (30 Days)
- COGT 1.8M
- ATLC 47.0K
- Earning Date
- COGT 08-05-2025
- ATLC 08-07-2025
- Dividend Yield
- COGT N/A
- ATLC N/A
- EPS Growth
- COGT N/A
- ATLC 35.13
- EPS
- COGT N/A
- ATLC 5.69
- Revenue
- COGT N/A
- ATLC $457,158,000.00
- Revenue This Year
- COGT N/A
- ATLC $274.30
- Revenue Next Year
- COGT N/A
- ATLC $12.69
- P/E Ratio
- COGT N/A
- ATLC $10.93
- Revenue Growth
- COGT N/A
- ATLC 26.20
- 52 Week Low
- COGT $3.72
- ATLC $30.00
- 52 Week High
- COGT $12.97
- ATLC $64.70
- Technical
- Relative Strength Index (RSI)
- COGT 59.54
- ATLC 71.70
- Support Level
- COGT $10.38
- ATLC $49.05
- Resistance Level
- COGT $12.21
- ATLC $62.86
- Average True Range (ATR)
- COGT 0.53
- ATLC 2.06
- MACD
- COGT -0.16
- ATLC 1.49
- Stochastic Oscillator
- COGT 64.13
- ATLC 92.66
About COGT Cogent Biosciences Inc.
Cogent Biosciences Inc a biotechnology company focused on developing precision therapies for genetically defined diseases. It designs rational precision therapies that treat the underlying cause of disease and improve the lives of patients. Its program CGT9486, is a selective tyrosine kinase inhibitor designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. In the vast majority of cases, KIT D816V is responsible for driving Systemic Mastocytosis (SM), a serious disease caused by the unchecked proliferation of mast cells. Exon 17 mutations are also found in patients with advanced gastrointestinal stromal tumors (GIST), a type of cancer with dependence on oncogenic KIT signaling.
About ATLC Atlanticus Holdings Corporation
Atlanticus Holdings Corp invests in the financial services industry. It provides various credit and related financial services and products to or associated with the financially underserved consumer credit market. The operating business segments are the Credit as a Service (CaaS) and the Auto Finance segment. It generates maximum revenue from the Credit as a Service segment.